Herbert Lim, MD
Gastroenterology · Honolulu, HINPI 1700892957
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 421 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 26.7% of the total. 2025 is the largest year on record at $5,113, 3.4 times the $1,497 reported in 2019. Among gastroenterology clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 421 payments — averaging $39.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Gilead$3K
- Boston Scientific$2K
- Pfizer$2K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$638
- plus $4K from 23 others
What the payments were for
- Travel & lodging$9266%
- Food & beverage$15,54194%
- Education$680%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 126 | $4,409 |
| Gilead | 94 | $2,685 |
| Boston Scientific | 12 | $1,758 |
| Pfizer | 65 | $1,608 |
| Johnson & Johnson | 15 | $1,007 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $638 |
| E.r. Squibb & Sons, L.L.C. | 24 | $601 |
| Madrigal Pharmaceuticals | 13 | $599 |
| Intercept Pharmaceuticals, Inc. | 8 | $578 |
| Exact Sciences | 5 | $345 |
| Alnylam Pharmaceuticals Inc. | 4 | $230 |
| Medtronic | 4 | $227 |
| Janssen Scientific Affairs, LLC | 2 | $224 |
| Fujifilm Healthcare Americas Corporation | 3 | $205 |
| Orphalan Inc | 2 | $180 |
| Sanofi | 1 | $148 |
| Ipsen Biopharmaceuticals, Inc | 2 | $147 |
| Regeneron | 1 | $129 |
| Exelixis Inc. | 1 | $128 |
| Novo Nordisk | 2 | $125 |
| Ardelyx, Inc. | 1 | $113 |
| AstraZeneca | 4 | $104 |
| Covidien LP | 1 | $87 |
| Ironwood Pharmaceuticals, Inc | 3 | $70 |
| Bristol Myers Squibb | 3 | $53 |
| Celltrion USA Inc. | 2 | $52 |
| Nestle Healthcare Nutrition Inc. | 2 | $37 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,535 in reported general payments places this provider in the 90th percentile of 71 gastroenterology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Entecavir | 40 | $37,879 |
| LinzessLinaclotide | 22 | $21,435 |
| Pantoprazole Sodium | 273 | $6,885 |
| Tenofovir Disoproxil Fumarate | 13 | $5,703 |
| Ursodiol | 26 | $5,330 |
| Mesalamine | 14 | $4,193 |
| Peg3350-Sod Sul-Nacl-Kcl-Asb-CPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 65 | $3,485 |
| Omeprazole | 107 | $2,738 |
| Famotidine | 95 | $2,415 |
| Esomeprazole Magnesium | 30 | $1,967 |
| Sucralfate | 14 | $882 |
| Dicyclomine Hcl | 13 | $590 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 32 | $472 |
| Enoxaparin Sodium | 13 | $457 |
| Lactulose | 17 | $447 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $4,409 | $21,43522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 71 gastroenterology providers in Hawaii.
Other gastroenterology in Honolulu
- Russell YangHonolulu$244K
- Roland TerHonolulu$37K
- Ankur JainHonolulu$8K
- Kraig YoungHonolulu$7K
- Brandon YimHonolulu$7K
- Traci MurakamiHonolulu$6K
- Jeong KimHonolulu$6K
- Gavin ParkHonolulu$5K
- Shilpa JainHonolulu$5K
- Carlson WongHonolulu$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.